[The role and mechanism of human trophoblastic cell surface antigen 2 in the invasion and metastasis of ovarian cancer]
- PMID: 33752309
- DOI: 10.3760/cma.j.cn112152-20200408-00322
[The role and mechanism of human trophoblastic cell surface antigen 2 in the invasion and metastasis of ovarian cancer]
Abstract
Objective: To explore the role and molecular mechanism of trophoblastic cell surface antigen 2 (Trop2) in the invasion and migration of ovarian cancer. Methods: Through the data mining of Cancer Cell Line Encyclopedia and TCGA database, the clinical significance of Trop2 expression was analyzed. Western blot was used to detect Trop2 protein expression in ovarian cancer cell lines including A3O, A1780 and SKOV3. SKOV3 cells were used to construct Trop2-short hairpin RNA (shRNA) cell model. Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was used to detect the SKOV3 mRNA expression in SKOV3-shRNA and SKOV3-NC cells. Cell counting kit-8 (CCK8) was used to detect the proliferation of SKOV3-shRNA cells and SKOV3-NC cells. Flow cytometry was used to detect cell cycle and apoptosis in two groups of cells. Transwell array was used to detecte the invasion and migration of SKOV3-shRNA cells and SKOV3-NC cells. Western blot was used to detect the protein expressions of AKT, p-AKT, β-catenin, caspase3, bcl-2, E-cadherin and vimentin. Results: Trop2 mRNA highly expressed in ovarian cancer, and was related to the tumor stage and patient survival. Compared with A3O cells, Trop2 overexpressed in A1780 and SKOV3 cells (P<0.05). The relative expression levels of Trop2 mRNA in SKOV3-NC group and SKOV3-shRNA group were 1.18±0.24 and 0.42±0.08, with statistically significant difference (P<0.05). The results of CCK-8 array showed that the cell viability of SKOV3-NC group was significantly higher than that of SKOV3-shRNA group (P<0.05). The proportion of G(0)/G(1) cells in SKOV3-NC and SKOV3-shRNA groups were (38.67±4.22)% and (60.24±8.17)%, respectively. G(0)/G(1) arrest was observed in SKOV3-shRNA cells (P<0.05). The apoptosis rate of SKOV3-shRNA group was (26.32±1.81)%, significantly higher than (6.54±1.32)% of SKOV3-NC group (P<0.05). The number of migrating SKOV3 cells in the SKOV3-shRNA and SkOV3-NC groups were 1 255.83±108.44 and 1 679.71±213.92, while the number of invading cells were 242.49±52.09 and 473.54±73.11, respectively. Compared with the SKOV3-NC group, the number of migrating and invading SKOV3-shRNA group was significantly reduced (all P<0.05). The expressions of p-AKT2, Bcl-2, vimentin and β-catenin were down-regulated, and the expressions of caspase 3 and E-cadherin were up-regulated in SKOV3-shRNA cells. There was no significant change in the total protein level of AKT. Conclusions: Trop2 expression is related to ovarian cancer stage and postoperative survival. Trop2 can promote ovarian cancer cell proliferation and metastasis by activating the AKT/β-catenin signaling pathway and knockdown of Trop2 inhibits the progression of ovarian cancer.
目的: 探讨人滋养层细胞表面抗原2(Trop2)在卵巢癌侵袭和转移中的作用及其分子机制。 方法: 通过对Cancer Cell Line Encyclopedia(CCLE)和The Cancer Genome Atlas(TCGA)数据库进行数据挖掘,分析Trop2表达的临床意义。采用Western blot法检测卵巢癌细胞系A3O、A1780和SKOV3中Trop2蛋白的表达。采用Trop2-shRNA构建SKOV3-shRNA细胞模型,以定量逆转录聚合酶链反应检测SKOV3-shRNA和SKOV3-NC组细胞中SKOV3 mRNA的表达,以细胞计数盒8法检测SKOV3-shRNA组和SKOV3-NC组细胞的增殖,以流式细胞仪检测SKOV3-shRNA和SKOV3-NC组细胞的细胞周期和凋亡,以Transwell实验检测SKOV3-shRNA和SKOV3-NC组细胞的侵袭和迁移,以Western blot法检测SKOV3-shRNA和SKOV3-NC组细胞中AKT、p-AKT、β-catenin、caspase3、bcl-2、E-cadherin和vimentin蛋白的表达。 结果: Trop2 mRNA在卵巢癌中高表达,其表达高低与肿瘤分期有关,也与患者预后有关。与A3O细胞比较,A1780和SKOV3细胞高表达Trop2蛋白(P<0.05)。SKOV3-NC组和SKOV3-shRNA组中Trop2 mRNA的相对表达量分别为1.18±0.24和0.42±0.08,差异有统计学意义(P<0.05)。SKOV3-NC组细胞的活力明显高于SKOV3-shRNA组(P<0.05)。SKOV3-NC和SKOV3-shRNA组G(0)/G(1)期细胞的比例分别为(38.67±4.22)%和(60.24±8.17)%,SKOV3-shRNA组细胞阻滞于G(0)/G(1)期(P<0.05)。SKOV3-shRNA组细胞的凋亡率为(26.32±1.81)%,明显高于SKOV3-NC组[(6.54±1.32)%,P<0.05]。SKOV3-shRNA组和SKOV3-NC组SKOV3细胞的迁移细胞数分别为(1 255.83±108.44)个/视野和(1 679.71±213.92)个/视野,侵袭细胞数分别为(242.49±52.09)个/视野和(473.54±73.11)个/视野,与SKOV3-NC组比较,SKOV3-shRNA组的迁移和侵袭细胞数均明显减少(均P<0.05)。SKOV3-shRNA细胞中p-AKT、bcl-2、vimentin、β-catenin表达下调,caspase3、E-cadherin表达上调,总AKT没有明显变化。 结论: Trop2的表达与卵巢癌分期和预后有关,Trop2可通过激活AKT/β-catenin信号通路促进卵巢癌细胞增殖和转移,沉默Trop2的表达可以抑制卵巢癌进展。.
Keywords: Invasion; Metastasis; Ovarian neoplasms; Prognosis.
Similar articles
-
[Effect of RBP2 gene silencing on proliferation, migration and invasion of ovarian epithelial cancer SKOV3/DDP cells and its mechanism].Zhonghua Zhong Liu Za Zhi. 2022 Feb 23;44(2):139-146. doi: 10.3760/cma.j.cn112152-20200612-00555. Zhonghua Zhong Liu Za Zhi. 2022. PMID: 35184457 Chinese.
-
[Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer].Zhonghua Fu Chan Ke Za Zhi. 2016 Apr 25;51(4):285-92. doi: 10.3760/cma.j.issn.0529-567X.2016.04.008. Zhonghua Fu Chan Ke Za Zhi. 2016. PMID: 27116987 Chinese.
-
[Effect of XPG down-regulation gene expression towards the proliferation of epithelial ovarian cancer cells and its chemosensitivity to platinum].Zhonghua Fu Chan Ke Za Zhi. 2012 Apr;47(4):286-91. Zhonghua Fu Chan Ke Za Zhi. 2012. PMID: 22781116 Chinese.
-
[Biological effect of down-regulating of MTRR gene on cisplatin-resistant ovarian cancer SKOV3 cells in vitro and in vivo studies].Zhonghua Fu Chan Ke Za Zhi. 2016 Feb;51(2):126-34. doi: 10.3760/cma.j.issn.0529-567X.2016.02.009. Zhonghua Fu Chan Ke Za Zhi. 2016. PMID: 26917482 Chinese.
-
Decoding TROP2 in breast cancer: significance, clinical implications, and therapeutic advancements.Front Oncol. 2023 Oct 24;13:1292211. doi: 10.3389/fonc.2023.1292211. eCollection 2023. Front Oncol. 2023. PMID: 37954074 Free PMC article. Review.
Cited by
-
A literature review of the promising future of TROP2: a potential drug therapy target.Ann Transl Med. 2022 Dec;10(24):1403. doi: 10.21037/atm-22-5976. Ann Transl Med. 2022. PMID: 36660684 Free PMC article. Review.
-
Trop2-Targeted Molecular Imaging in Solid Tumors: Current Advances and Future Outlook.Mol Pharm. 2024 Dec 2;21(12):5909-5928. doi: 10.1021/acs.molpharmaceut.4c00848. Epub 2024 Nov 13. Mol Pharm. 2024. PMID: 39537365 Review.
-
TROP2 modulates the progression in papillary thyroid carcinoma.J Cancer. 2021 Sep 27;12(22):6883-6893. doi: 10.7150/jca.62461. eCollection 2021. J Cancer. 2021. PMID: 34659576 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous